Investor Alert

Market Pulse Archives

March 24, 2021, 8:37 a.m. EDT

Twist's COVID-19 test, which can detect variants, gets authorized

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Twist Bioscience Corp. (TWST)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Twist Bioscience Corp. /zigman2/quotes/207089457/composite TWST +4.26% were down 1.6% in premarket trading on Wednesday after the company said its in-vitro diagnostic test that can detect SARS-CoV-2 RNA received emergency authorization in the U.S. Twist's test can identify the presence of the virus from a patient sample; it can also be used by Biotia Inc.'s software system to analyze the sequence and detect any genetic variants. So-called "variants of concern" have emerged over the last six months, including the B.1.1.7 variant out of the U.K., which is thought to be more infectious and makes up to 30% of all new U.S. cases, according to the Centers for Disease Control and Prevention. "This test opens the door to a new diagnostic method and can also guide vaccine research, since it captures viral variants so well," Biotia co-founder Christopher Mason said in a news release. Biota is a privately held company. Twist's stock has soared 390.6% over the past 12 months, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.25% is up 74.8%.

US : U.S.: Nasdaq
$ 29.15
+1.19 +4.26%
Volume: 741,304
Jan. 27, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.58 billion
Rev. per Employee
+10.13 +0.25%
Volume: 0.00
Jan. 27, 2023 5:10p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.